Tag: Immunocompromised patients

Despite being discovered in 2001, there is still no specific antiviral medication currently recommended or approved to treat human metapneumovirus (hMPV). Consequently, the question, "Is there a drug of choice for metapneumovirus?" is frequently asked, and the answer centers on supportive care, with specific therapies only considered in severe cases among high-risk individuals.

While initial human clinical trials showed that pritelivir was generally well-tolerated with common adverse events like nausea and headache, a 2013 FDA hold due to safety signals in animal studies highlighted important safety considerations. This new antiviral is still under investigation, specifically for immunocompromised individuals with drug-resistant herpes.

Over one-quarter of the world's population is affected by cutaneous fungal infections, a major reason for the widespread use of antifungal medications. The indications of antifungal drugs cover a vast spectrum, from superficial infections of the skin and nails to life-threatening systemic mycoses that can affect internal organs. These medications are crucial tools in modern medicine for managing both common and severe fungal diseases.

According to the Centers for Disease Control and Prevention (CDC), the primary medication used to treat *Isospora* (now officially *Cystoisospora belli*) infection is the antibiotic combination Trimethoprim-sulfamethoxazole (TMP-SMX). This article explores in detail what antibiotic is used for Isospora, outlining the standard regimen, alternative options, and considerations for different patient populations.